Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.77 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993594 | 0.90 | KIF11 (0.71) | KIF11ABCG2ABCB1TP53MAPT | |
| SCHEMBL3571437 | 0.90 | KIF11 (0.78) | KIF11ABCG2ABCB1TP53MAPT | |
| SCHEMBL3577680 | 0.87 | KIF11 (1.00) | KIF11 | |
| SCHEMBL3568488 | 0.86 | KIF11 (0.80) | KIF11 | |
| SCHEMBL3577188 | 0.86 | KIF11 (0.80) | KIF11 | |
| SCHEMBL3573923 | 0.82 | KIF11 (0.83) | KIF11 | |
| SCHEMBL3577511 | 0.81 | KIF11 (0.81) | KIF11 | |
| SCHEMBL764898 | 0.80 | TP53 (0.66) | KIF11ABCG2ABCB1TP53MAPT | |
| SCHEMBL2707877 | 0.80 | MAPKAPK2 (0.62) | ABCG2ABCB1TP53MAPT | |
| SCHEMBL16301440 | 0.80 | KIF11 (0.60) | KIF11ABCG2ABCB1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855295-B2 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855295-B2 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855295-B2 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-1706404-A2 | TETRAHYDROCARBOLINE COMPOUNDS AS ANTICANCER AGENTS | Chiron Corporation (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050215580-A1 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005070930-A2 | TETRAHYDROCARBOLINE COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215580-A1 | Tetrahydrocarboline compounds as anticancer agents | MTHFD1, BAD, DHFR | KIF11 2735/4885ABCG2 314/4885ABCB1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.